(0.32%) 5 116.27 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.97%) $83.04
(5.25%) $2.02
(0.28%) $2 353.70
(0.42%) $27.65
(4.15%) $960.40
(-0.27%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer...
Stats | |
---|---|
本日の出来高 | 42 309.00 |
平均出来高 | 2.45M |
時価総額 | 20.47M |
EPS | $0 ( 2024-04-28 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.04 |
ATR14 | $0.0420 (0.86%) |
ボリューム 相関
Aptorum Group Ltd 相関
10 最も負の相関 | |
---|---|
PUCK | -0.948 |
THCPU | -0.947 |
OVLY | -0.945 |
BRACU | -0.942 |
XM | -0.939 |
NCAC | -0.935 |
WFRD | -0.935 |
INOD | -0.935 |
TGTX | -0.934 |
MCAA | -0.933 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aptorum Group Ltd 相関 - 通貨/商品
Aptorum Group Ltd 財務諸表
Annual | 2022 |
収益: | $1.30M |
総利益: | $80 065.00 (6.18 %) |
EPS: | $-14.89 |
FY | 2022 |
収益: | $1.30M |
総利益: | $80 065.00 (6.18 %) |
EPS: | $-14.89 |
FY | 2021 |
収益: | $1.54M |
総利益: | $81 854.00 (5.31 %) |
EPS: | $-7.94 |
FY | 2020 |
収益: | $911 509 |
総利益: | $-103 514 (-11.36 %) |
EPS: | $2.24 |
Financial Reports:
No articles found.
Aptorum Group Ltd
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。